IVA - Inventiva S.A.
After hours:
| Previous Close | 3.8500 |
| Open | 3.9900 |
| Bid | 3.8900 x 1300 |
| Ask | 4.3000 x 2200 |
| Day's Range | 3.6200 - 4.0900 |
| 52 Week Range | 2.2200 - 11.7500 |
| Volume | |
| Avg. Volume | 30,384 |
| Market Cap | 164.312M |
| Beta (5Y Monthly) | 1.17 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.7800 |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
GlobeNewswireResults of the votes of the Combined Shareholders’ General Meeting of May 25, 2023
Daix (France), Long Island City (New York, United States), May 26, 2023 – Inventiva (Euronext Paris and Nasdaq: IVA), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH) and other diseases with unmet medical need, today announced the results of the votes of its Combined Shareholders’ Meeting. The Combined Shareholders' Meeting was held on Thursday May 25, 2023 at 2 p.m. at Hôtel Oceania L
- GlobeNewswire
Inventiva announces that its partner Sino Biopharm received IND approval from the NMPA to initiate clinical trial with lanifibranor in China
Chia Tai Tianqing Pharmaceutical Group Co., Ltd., a Sino Biopharm’s subsidiary, receives IND approval from the NMPA to initiate the clinical development in mainland China of lanifibranor in NASHSino Biopharm will participate in the ongoing NATiV3 Phase III trial which, if positive, is expected to support a potential NDA filing in ChinaIn parallel, Sino Biopharm will conduct a Phase I clinical pharmacology studyFollowing this regulatory decision, Inventiva is eligible to the first of the 2 short
- GlobeNewswire
Description of the Share Repurchase Program Authorised by the Ordinary General Meeting of 25 May 2023
Daix, 25 May 2023 Pursuant to Article 241-2 of the AMF General Regulations (Règlement Général de l’Autorité des marchés financiers), the purpose of this description is to present the objectives and terms of the Company’s share repurchase program approved by the Ordinary General Meeting of 25 May 2023. Securities concerned: shares issued by Inventiva SA.Maximum proportion of capital that may be purchased by the Company: 10%.Maximum number of its own shares that may be acquired by the Company, bas
- GlobeNewswire
Inventiva reports 2023 First Quarter Financial Information¹ and provides a corporate update
Cash and cash equivalents at €56.3 million, short-term deposits at €0.7 million2, and long term deposit at €9.3 million3 as of March 31, 2023, compared to €86.7 million, €1.0 million and €0.7 million as of December 31, 2022, respectivelyImprovements on NATiV3 Phase III clinical trial with lanifibranor in NASH with the implementation of the new design, progress in patient recruitment and recommendation, following the second meeting of the Data Monitoring Committee, to continue the trial without m
- GlobeNewswire
Statement of total voting rights and shares forming the company’s share capital as of April 17, 2023
Article R. 22-10-23 of the French Commercial Code Market : Euronext ParisISIN code / Mnemo : FR0013233012 / IVAWeb site : www.inventivapharma.com Date Number of Shares Outstanding Total voting rights,gross (1) Total voting rights,net (2) 17 April 2023 42 134 169 55 141 851 55 991 581 (1) The total number of gross (or “theoretical”) voting rights is used as the basis for calculating threshold crossings. In accordance with Article 223-11 of the AMF General Regulations, this number is calculated on
- GlobeNewswire
Combined General Meeting of May 25, 2023. Availability of the preparatory documents
Daix (France), Long Island City (New York, United States), May 4, 2023 – Inventiva (Euronext Paris and Nasdaq: IVA), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of patients with non-alcoholic steatohepatitis (NASH) and other diseases with significant unmet medical needs, today announced the availability of the preparatory documents for the Combined General Meeting of May 25, 2023. Shareholders are invited to participate
- GlobeNewswire
Inventiva announces filing of its 2022 Universal Registration Document and 2022 Annual Report on Form 20-F
Daix (France), Long Island City (New York, United States), March 30, 2023 Inventiva (Euronext Paris and Nasdaq: IVA), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH) and other diseases with significant unmet medical needs, today announced that it had filed its 2022 Universal Registration Document for the year ended December 31, 2022, including the management report and the annual fina
- GlobeNewswire
Inventiva reports its 2022 full-year results
Cash and cash equivalents at €86.7 million and short term deposits at €1 million as of December 31, 2022 compared to €86.6 million and €8.8 million, respectively as of December 31, 2021 Inventiva entered into a license and collaboration agreement with Sino Biopharm a leading Chinese pharmaceutical group, through CTTQ, to develop, manufacture and commercialize lanifibranor in Greater China Under this agreement with Sino Biopharm, Inventiva received a €12.8 million¹ upfront payment Inventiva recei
- GlobeNewswire
Inventiva announces the schedule of publication and presentation of its 2022 Full-Year Financial Results
Daix (France), Long Island City (New York, United States), March 23, 2023 – Inventiva (Euronext Paris and Nasdaq: IVA) (the “Company”), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of patients with non-alcoholic steatohepatitis (NASH) and other diseases with significant unmet medical needs, today announced that its management team will host a webcast to present the Company’s 2022 full-year financial results on Thursday,
- GlobeNewswire
Correction: Inventiva reports preliminary financial results for Full-Year 2022¹
Daix (France), Long Island City (New York, United States), February 14, 2023 – Inventiva (Euronext Paris and Nasdaq: IVA) (the “Company”), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of patients with non-alcoholic steatohepatitis (“NASH”) and other diseases with significant unmet medical needs, today reported certain preliminary financial results as of and for the year ended December 31, 2022. Preliminary Financial Resu
- GlobeNewswire
Inventiva reports preliminary financial results for Full-Year 2022¹
Daix (France), Long Island City (New York, United States), February 14, 2023 – Inventiva (Euronext Paris and Nasdaq: IVA) (the “Company”), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of patients with non-alcoholic steatohepatitis (“NASH”) and other diseases with significant unmet medical needs, today reported certain preliminary financial results as of and for the year ended December 31, 2022. Preliminary Financial Resu
- GlobeNewswire
Half-Year Review of Inventiva’s Liquidity Contract with Kepler Cheuvreux
Daix (France), Long Island City (New York, United States), January 30, 2023 – Inventiva (Euronext Paris and Nasdaq: IVA) (the “Company”), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of patients with non-alcoholic steatohepatitis (NASH) and other diseases with significant unmet medical needs, today announced the half-year report of its liquidity contract with Kepler Cheuvreux.Under the liquidity contract granted to Keple
- GlobeNewswire
Results of the votes of the Combined Shareholders’ General Meeting of January 25, 2023
Daix (France), Long Island City (New York, United States), January 26, 2023 – Inventiva (Euronext Paris and Nasdaq: IVA), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH) and other diseases with unmet medical need, today announced the results of the votes of its Combined Shareholders’ General Meeting. The Combined Shareholders' Meeting was held on January 25, 2023 at 2 p.m. at Hôtel Oc
- GlobeNewswire
Inventiva announces changes to the clinical development of lanifibranor, including plans for a new Phase III trial in patients with NASH and compensated cirrhosis
Proposed changes are expected to be beneficial to the lanifibranor clinical program by reducing the number of biopsies and the trial duration, eventually offering all patients in the trial access to treatment and potentially expanding the addressable patient population to patients with NASH and compensated cirrhosis Confirmatory trial of lanifibranor clinical benefits, which was initially planned to be evaluated in Part 2 of NATiV3 trial in patients with NASH and F2/F3 fibrosis, is now planned t
- GlobeNewswire
Statement of total voting rights and shares forming the company’s share capital as of December 19, 2022
Article R. 22-10-23 of the French Commercial Code Market : Euronext ParisISIN code / Mnemo : FR0013233012 / IVAWeb site : www.inventivapharma.com Date Number of Shares Outstanding Total voting rights, gross (1) Total voting rights, net (2) December 19, 2022 42 134 169 55 144 801 55 029 868 (1) The total number of gross (or “theoretical”) voting rights is used as the basis for calculating threshold crossings. In accordance with Article 223-11 of the AMF General Regulations, this number is calcula
- GlobeNewswire
Combined General Meeting of January 25, 2023 - Availability of the preparatory documents
Daix (France), Long Island City (New York, United States), January 3, 2023 – Inventiva (Euronext Paris and Nasdaq: IVA), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of patients with non-alcoholic steatohepatitis (NASH) and other diseases with significant unmet medical needs, today announced the availability of the preparatory documents for the Combined General Meeting of January 25, 2023. Shareholders are invited to par
- GlobeNewswire
Inventiva draws down €25 million tranche under Finance Contract with the European Investment Bank
Inventiva intends to use the proceeds to fund part of the pivotal Phase III clinical trial evaluating lanifibranor in patients with NASHThe €25 million supports Inventiva’s anticipated cash runway1 through the fourth quarter of 2023 Daix (France), Long Island City (New York, United States), December 12, 2022 – Inventiva (Euronext Paris and Nasdaq: IVA) (the “Company”), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of pati
- GlobeNewswire
Inventiva secures a new patent expanding the IP protection of its lead product candidate lanifibranor in the US
New patent granted in the United States by the USPTO covers the use of lanifibranor for the potential treatment of cirrhotic patients at risk of progressing from compensated stage to decompensated stage This patent strengthens and expands the intellectual property protection of lanifibranor in the United States particularly for use for patients with cirrhotic NASH Daix (France), Long Island City (New York, United States), November 28, 2022 – Inventiva (Euronext Paris and Nasdaq: IVA) (the “Compa
- GlobeNewswire
Inventiva announces a new Director of the Board of Directors
Daix (France), Long Island City (New York, United States), November 21, 2022 – Inventiva (Euronext Paris and Nasdaq: IVA), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of nonalcoholic steatohepatitis (NASH) and other diseases with significant unmet medical needs, today announces that, effective on November 9th, 2022, Inventiva’s board of directors coopted Dr. Lucy Lu as the Director of its Board of Directors in lieu of S
- GlobeNewswire
Inventiva reports 2022 Third Quarter Financial Information¹
Cash position2 at €72.6m as of September 30, 2022, not including the $12.6 million upfront payment received from Sino Biopharm on November 4, 2022Revenues of €0.1m for the first nine months of 2022 Daix (France), Long Island City (New York, United States), November 10, 2022 – Inventiva (Euronext Paris and Nasdaq: IVA) (the “Company”), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of patients with non-alcoholic steatohepat
ZacksTake the Zacks Approach to Beat the Market: Caterpillar, Amgen, Inventiva in Focus
Our time-tested methodologies were at work to help investors navigate the market well last week. Here are some of our key performance data from the past three months.
- GlobeNewswire
Inventiva provides an update on the development of cedirogant by AbbVie
Daix (France), Long Island City (New York, United States), October 31, 2022 – Inventiva (Euronext Paris and Nasdaq: IVA), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH), mucopolysaccharidoses (MPS) and other diseases with significant unmet medical needs, today announced that AbbVie communicated during their third-quarter financial results1 on Friday October 28th, that they decided to
- GlobeNewswire
Inventiva announces a scientific presentation at the AASLD The Liver Meeting® 2022
Daix (France), Long Island City (New York, United States), October 21, 2022 – Inventiva (Euronext Paris and Nasdaq: IVA), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of nonalcoholic steatohepatitis (NASH) and other diseases with significant unmet medical needs, today announced that a scientific abstract has been selected for poster presentation at the upcoming The Liver Meeting® 2022 hosted by the American Association f
- GlobeNewswire
Inventiva reports its 2022 first-half financial results and provides a corporate update
Cash position1 at €87.2 million as of June 30, 2022, compared to €95.4 million as of December 31, 2021 Receipt of a €4 million milestone payment from Inventiva’s partner AbbVie for cedirogant Phase IIb clinical trial initiation accounted for in 2021 revenues and H1 2022 cash flowInventiva entered into a credit facility for up to €50 million, subject to conditions, and a related warrant agreement with the European Investment Bank (EIB)2Inventiva raised approximately €14.7 million through a combin
- GlobeNewswire
Inventiva and Sino Biopharm announce licensing and collaboration agreement to develop and commercialize lanifibranor in Greater China
Sino Biopharm a leading Chinese pharmaceutical group, through CTTQ will oversee the development and commercialization of lanifibranor in Greater ChinaLanifibranor is an orally-available small molecule with breakthrough therapy designation from the U.S. Food and Drug Administration (FDA) following a positive Phase IIb trial in patients with non-alcoholic steatohepatitis (NASH). Lanifibranor is currently evaluated in a pivotal Phase III trial in NASHInventiva will receive a $12 million upfront, $5